RxDoctor Payments Data

William Brown, MD

Internal Medicine · Clearwater, FLNPI 1396741088

Payments from drug & device makers

$4,199in general payments, 2019–2025

Across 226 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$470
  • AstraZeneca$470
  • AbbVie$368
  • Amarin Pharma, Inc.$304
  • Pfizer$294
  • Boehringer Ingelheim$286
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,14999%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,199 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$226,793
Medicare patients
411
Services billed
2,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$82,727
XareltoRivaroxaban45$57,944
MounjaroTirzepatide52$53,730
JardianceEmpagliflozin52$50,641
OzempicSemaglutide30$34,217
JanuviaSitagliptin Phosphate19$30,850
DescovyEmtricitabine/Tenofov Alafenam11$27,572
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$26,740
UbrelvyUbrogepant12$22,346
TradjentaLinagliptin16$14,904
FarxigaDapagliflozin Propanediol18$12,536
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$9,506
Repatha SyringeEvolocumab13$7,138
Amoxicillin-Clavulanate Pot ErAmoxicillin/Potassium Clav16$5,107
Levothyroxine Sodium563$5,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$294$85,291112 claims
Boehringer IngelheimJardiance, Tradjenta$286$65,54668 claims
Johnson & JohnsonXarelto$268$57,94445 claims
Lilly USA, LLCMounjaro$168$53,73052 claims
GSKTrelegy Ellipta, Anoro Ellipta$470$36,24650 claims
Novo NordiskOzempic$247$34,21730 claims
MerckJanuvia$87$30,85019 claims
AbbVieUbrelvy, Synthroid$368$25,24354 claims
AstraZenecaFarxiga, Symbicort$470$15,15629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →